Targeted Alpha-emitter Therapy of PRRT Naive Neuroendocrine Tumor Patients (ALPHAMEDIX02)

  • STATUS
    Recruiting
  • End date
    Dec 1, 2023
  • participants needed
    34
  • sponsor
    Radiomedix, Inc.
Updated on 22 March 2022

Summary

Multicenter Phase 2 study of 212Pb-DOTAMTATE enrolling adult subjects with positive somatostatin positive neuroendocrine tumors with no prior history of peptide receptor radionuclide therapy (PRRT naive)

Description

In this open-label, multicenter, single-arm Phase 2 study, adult subjects with histologically confirmed NETs and positive somatostatin analog imaging, with no prior PRRT (PRRT naive) will be enrolled to receive 212Pb-DOTAMTATE 67.6 μCi/kg dose per cycle

Details
Condition Neuroendocrine Tumors
Treatment AlphaMedix
Clinical Study IdentifierNCT05153772
SponsorRadiomedix, Inc.
Last Modified on22 March 2022

Eligibility

Yes No Not Sure

Inclusion Criteria

Male or female ≥18 years old with unresectable or metastatic histologically confirmed NET
Documented progression of disease following previous therapy within 12 months prior to enrollment and the presence of at least 1 site of measurable disease per RECIST 1.1
Subjects must have received and progressed following somatostatin analog administration
Confirmed presence of somatostatin receptors on all lesions including the non-target and measurable lesions documented by CT/MRI scans, based on positive 68Ga-DOTATATE (NETSPOT®), 64Cu-DOTATATE (Detectnet™), or other FDA approved SSTR PET/CT imaging within 6 weeks prior to enrollment. Follow up imaging should be performed with the same agent or modality used at baseline
Target lesions must be positive (greater than grade 2 uptake Krenning Score) or must have an SUV of more than the normal liver background
Lytic bone lesions, with an identifiable soft tissue component, evaluated by CT or MRI, can also be considered measurable lesions if the soft tissue component otherwise meets the definition of measurability according to RECIST 1.1. In any case, osteoblastic bone lesions are not measurable
Eastern Cooperative Oncology Group (ECOG) status 0-2
Life expectancy of at least 12 weeks in the opinion of the investigator at the time of screening
Sufficient bone marrow capacity and organ function in the recent blood tests within 3 weeks prior to Day 1, as defined by
White blood cell (WBC) ≥2,500/ mm3
Absolute neutrophil count (ANC) ≥1000/mm3
Platelets ≥100,000/mm3
Hemoglobin (HgB) ≥9.0 g/dL
Alanine aminotransferase (ALT) and Aspartate aminotransferase (AST) ≤3 X upper limit of normal (ULN)
Total Bilirubin: ≤2 X ULN
Serum creatinine ≤1.7 mg/dL
Serum albumin ≥3.0 g/L; if lower than 3.0 g/L requires normal range prothrombin time (PT) and international normalized ratio (INR), and
Be willing to practice the following medically acceptable methods of birth control
(both women of childbearing potential (WOCBP) and men who have partners of
childbearing potential) from the Screening Visit through 3 months after the
final administration 212Pb-DOTAMTATE

Exclusion Criteria

Prior whole-body radiotherapy or PRRT using 177Lu/90Y/111In-DOTATATE/ DOTATOC or TAT
Prior regional hepatic radionuclide therapy within 4 months prior to enrollment or prior nonradioactive regional hepatic therapy within 6 months prior to enrollment
Known hypersensitivity to somatostatin analogues, AA infusion, or 212Pb-DOTAMTATE
Therapeutic use of any somatostatin analogue, including Sandostatin® LAR (within 28 days) and Sandostatin® (within 1 day) prior to administration of study drug
History of myelodysplastic syndrome (MDS)
Female subjects who are pregnant or lactating
Indication for surgical lesion removal with curative potential
Known brain metastases, unless these metastases have been treated and/or stable for 6 months prior to enrollment
Experimental cancer treatments or other investigational therapies within 6 weeks or five half-lives of the investigational medication prior to Day 1
Uncontrolled congestive heart failure (NYHA II, III, IV)
Uncontrolled diabetes mellitus as defined by a hemoglobin A1C >10.0
Evidence of renal obstruction based on Tc-99m DTPA or TER for MAG3 renal scintigraphy or renal ultrasound
Known or active human immunodeficiency virus (HIV) or hepatitis B or C virus unless cured
Known or suspected active drug or alcohol abuse
Participation in other interventional clinical studies within 30 days prior to Day 1
Other known co-existing malignancies except non-melanoma skin cancer and carcinoma in situ of the uterine cervix, unless definitively treated and proven no evidence of recurrence for 5 years
Any somatic or psychiatric disease/condition or abnormal laboratory test that in the opinion of the investigator, may interfere with the objectives and assessments of the study; or
Unable to comply with the requirements of the study protocol or be unsuitable for the study for any reason, in the opinion of the investigator
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note